Compare EXPO & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EXPO | LQDA |
|---|---|---|
| Founded | 1967 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.1B |
| IPO Year | 1996 | 2020 |
| Metric | EXPO | LQDA |
|---|---|---|
| Price | $66.56 | $37.68 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 11 |
| Target Price | ★ $88.00 | $41.00 |
| AVG Volume (30 Days) | 425.4K | ★ 1.1M |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.86% | N/A |
| EPS Growth | N/A | ★ 51.81 |
| EPS | ★ 2.07 | N/A |
| Revenue | ★ $582,014,000.00 | $158,320,000.00 |
| Revenue This Year | $12.75 | $265.61 |
| Revenue Next Year | $8.50 | $62.82 |
| P/E Ratio | $32.11 | ★ N/A |
| Revenue Growth | 4.21 | ★ 1031.18 |
| 52 Week Low | $63.25 | $11.26 |
| 52 Week High | $83.92 | $46.67 |
| Indicator | EXPO | LQDA |
|---|---|---|
| Relative Strength Index (RSI) | 45.42 | 55.50 |
| Support Level | $64.55 | $31.75 |
| Resistance Level | $73.91 | $39.19 |
| Average True Range (ATR) | 2.17 | 1.81 |
| MACD | 0.11 | 0.21 |
| Stochastic Oscillator | 54.67 | 79.95 |
Exponent Inc is a science and engineering consulting firm that provides solutions to complex problems. The company's consultant team is composed of scientists, physicians, engineers, as well as business and regulatory consultants. The company currently operates through two segments. The engineering and other scientific segments, which account for the majority of revenue, provide servicing encompassing biomechanics, biomedical engineering, buildings and structures, civil engineering, construction consulting, etc. The environmental and health segment covers chemical regulation and food safety, ecological and biological sciences, environmental and earth sciences and others. The company generates almost all of its revenues from America.
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.